[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560004":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":13,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":56,"collaborators":13,"id":58,"slug":13,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":13,"studyType":71,"phases":13,"briefSummary":72,"conditions":73,"keywords":13,"overallStatus":39,"whyStopped":13,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Missouri-Columbia","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Beta-cell function","Insulin secretion rate in relationship to plasma glucose","before and 7 days after rhGH administration",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","The study population will consist of obese men and women ages 18-45 with and without a first degree relative with type 2 diabetes.",[19,21],{"label":20,"type":13,"description":13,"interventionNames":13},"Men and women with a family history of type 2 diabetes",{"label":22,"type":13,"description":13,"interventionNames":13},"Men and women without a family history of type 2 diabetes",[24],{"name":25,"affiliation":5,"role":26},"Bettina Mittendorfer, PhD","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":13,"email":32},"Amanda Heider","CONTACT","573-884-6852","ahmc4@health.missouri.edu",{"name":34,"role":30,"phone":13,"phoneExt":13,"email":35},"Vasavi Shabrish, PhD","v.shabrish@missouri.edu",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of Missouri School of Medicine","RECRUITING","Columbia","Missouri","65212","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-92.33407,38.95171,{"lat":49,"lon":48},[52],{"name":53,"role":30,"phone":54,"phoneExt":13,"email":55},"Bettina Mittendorfer","573-882-9377","b.mittendorfer@missouri.edu",{"type":26,"investigatorFullName":53,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Senior Associate Dean for Research; Professor, Medicine & Nutrition; NextGen Director of Clinical and Translational Sciences Unit","100560004",false,"NCT06571500","Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes","GHRB-B","Inclusion Criteria:\n\n* 18 to 59 years old\n* body mass index ≥30.0 kg\u002Fm2 and \\\u003C45.0 kg\u002Fm2\n\nAdditional, group-specific inclusion criteria:\n\n* Family history of type 2 diabetes: first degree relative with type 2 diabetes\n* Control group: no family history of type 2 diabetes\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant during the study, or breastfeeding\n* Current diagnosis or history of type 1 or type 2 diabetes\n* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* History of bariatric surgery\n* Known, uncontrolled hypothyroidism\n* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* Current cancer or cancer that has been in remission less than 5 years\n* First degree relative with type 1 diabetes diagnosis\n* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* Alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration\n* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent",true,"ALL","18 Years","59 Years",{"count":69,"type":70},30,"ESTIMATED","OBSERVATIONAL","The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[74,75],"Healthy","Obesity","2026-05-05",{"date":78,"type":79},"2026-05-11","ACTUAL",{"date":81,"type":79},"2025-07-15",{"date":83,"type":70},"2030-09-01",{"name":5,"class":6},1]